Programs Advancing Toward the Clinic
Oncorus is advancing a pipeline of IV-administered saRNA medicines across solid tumor and hematologic malignancy indications, from preclinical research through clinical evaluation.
Pipeline Overview
Our programs are designed to leverage the unique properties of self-amplifying RNA — systemic delivery, sustained expression, and multi-arm immune activation — to address tumor types with significant unmet medical need.
Program Details
Solid Tumors
Tumor Microenvironment Reprogramming
ONC-001 is an IV-administered saRNA encoding a potent immunostimulatory payload designed to reprogram the immunosuppressive tumor microenvironment and activate cytotoxic T cell responses in solid tumors.
- IV administration enabling systemic tumor access
- Phase 1 dose-escalation study ongoing in advanced solid tumors
- Combination potential with checkpoint inhibitors under evaluation
Hematologic Malignancies
Tumor-Selective Cytotoxicity
ONC-002 is a tumor-targeted saRNA program in preclinical development for hematologic malignancies, designed to selectively kill malignant cells while sparing healthy hematopoietic tissue.
- Tumor-selective targeting mechanism validated in vitro and in vivo
- IND-enabling studies in progress
- Potential best-in-class profile vs. existing targeted therapies
Solid Tumors — Combination
Dual Innate/Adaptive Activation
ONC-003 is an early-stage discovery program exploring multi-payload saRNA constructs designed to simultaneously engage innate and adaptive immune pathways for combination use with standard-of-care chemotherapy.
- Multi-payload saRNA construct design underway
- Preclinical proof-of-concept studies initiated
- Designed for combination with standard-of-care chemotherapy
Partnering & Collaboration
Oncorus is actively seeking scientific and clinical collaborators to advance our pipeline programs. We welcome discussions with academic medical centers, cooperative groups, and biopharmaceutical partners.